Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.
Can Alto Neuroscience turn an overlooked Parkinson’s drug into a major depression breakthrough?
Can Alto Neuroscience’s ALTO-207 change treatment-resistant depression care? Read what the new Phase 2b trial could mean for psychiatry.
What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia
Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.
FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?
Soterix Medical wins FDA clearance for SPRY TMS in treatment-resistant major depression. What the clearance means for the neuromodulation market. Read the analysis.
Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development
Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.